Titre : Feuillets embryonnaires

Feuillets embryonnaires : Questions médicales fréquentes

Termes MeSH sélectionnés :

Prostatic Neoplasms
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Feuillets embryonnaires : Questions médicales les plus fréquentes", "headline": "Feuillets embryonnaires : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Feuillets embryonnaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-24", "dateModified": "2025-04-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Feuillets embryonnaires" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Structures de l'embryon", "url": "https://questionsmedicales.fr/mesh/D004628", "about": { "@type": "MedicalCondition", "name": "Structures de l'embryon", "code": { "@type": "MedicalCode", "code": "D004628", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ectoderme", "alternateName": "Ectoderm", "url": "https://questionsmedicales.fr/mesh/D004475", "about": { "@type": "MedicalCondition", "name": "Ectoderme", "code": { "@type": "MedicalCode", "code": "D004475", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.273" } } }, { "@type": "MedicalWebPage", "name": "Endoderme", "alternateName": "Endoderm", "url": "https://questionsmedicales.fr/mesh/D004707", "about": { "@type": "MedicalCondition", "name": "Endoderme", "code": { "@type": "MedicalCode", "code": "D004707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.407" } } }, { "@type": "MedicalWebPage", "name": "Mésoderme", "alternateName": "Mesoderm", "url": "https://questionsmedicales.fr/mesh/D008648", "about": { "@type": "MedicalCondition", "name": "Mésoderme", "code": { "@type": "MedicalCode", "code": "D008648", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.660" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Péricytes", "alternateName": "Pericytes", "url": "https://questionsmedicales.fr/mesh/D020286", "about": { "@type": "MedicalCondition", "name": "Péricytes", "code": { "@type": "MedicalCode", "code": "D020286", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.660.600" } } }, { "@type": "MedicalWebPage", "name": "Somites", "alternateName": "Somites", "url": "https://questionsmedicales.fr/mesh/D019170", "about": { "@type": "MedicalCondition", "name": "Somites", "code": { "@type": "MedicalCode", "code": "D019170", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A16.504.660.750" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Feuillets embryonnaires", "alternateName": "Germ Layers", "code": { "@type": "MedicalCode", "code": "D005855", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elizabeth R Gavis", "url": "https://questionsmedicales.fr/author/Elizabeth%20R%20Gavis", "affiliation": { "@type": "Organization", "name": "Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America." } }, { "@type": "Person", "name": "Bernard K van der Veer", "url": "https://questionsmedicales.fr/author/Bernard%20K%20van%20der%20Veer", "affiliation": { "@type": "Organization", "name": "Laboratory for Stem Cell and Developmental Epigenetics, Department of Development and Regeneration, Katholieke Universiteit Leuven, 3000 Leuven, Belgium." } }, { "@type": "Person", "name": "Kian Peng Koh", "url": "https://questionsmedicales.fr/author/Kian%20Peng%20Koh", "affiliation": { "@type": "Organization", "name": "Laboratory for Stem Cell and Developmental Epigenetics, Department of Development and Regeneration, Katholieke Universiteit Leuven, 3000 Leuven, Belgium." } }, { "@type": "Person", "name": "Ulrich Technau", "url": "https://questionsmedicales.fr/author/Ulrich%20Technau", "affiliation": { "@type": "Organization", "name": "Department for Molecular Evolution and Development, Centre of Organismal Systems Biology, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria ulrich.technau@univie.ac.at." } }, { "@type": "Person", "name": "Patrick P L Tam", "url": "https://questionsmedicales.fr/author/Patrick%20P%20L%20Tam", "affiliation": { "@type": "Organization", "name": "Embryology Research Unit, Children's Medical Research Institute, and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?", "datePublished": "2023-02-03", "url": "https://questionsmedicales.fr/article/36718727", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/14737140.2023.2171991" } }, { "@type": "ScholarlyArticle", "name": "The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.", "datePublished": "2023-05-02", "url": "https://questionsmedicales.fr/article/37534902", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4103/aja20239" } }, { "@type": "ScholarlyArticle", "name": "Simultaneous thulium laser resection of the prostate and transperineal prostate biopsy in clinically diagnosed metastatic prostate cancer with bladder outlet obstruction.", "datePublished": "2023-08-18", "url": "https://questionsmedicales.fr/article/37596454", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10103-023-03848-5" } }, { "@type": "ScholarlyArticle", "name": "Staging Prostate Cancer with", "datePublished": "2023-04-28", "url": "https://questionsmedicales.fr/article/37116912", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2967/jnumed.122.265371" } }, { "@type": "ScholarlyArticle", "name": "Complexities of Prostate Cancer.", "datePublished": "2022-11-17", "url": "https://questionsmedicales.fr/article/36430730", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms232214257" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Structures de l'embryon", "item": "https://questionsmedicales.fr/mesh/D004628" }, { "@type": "ListItem", "position": 3, "name": "Feuillets embryonnaires", "item": "https://questionsmedicales.fr/mesh/D005855" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Feuillets embryonnaires - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Feuillets embryonnaires", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Feuillets embryonnaires", "description": "Comment identifier les feuillets embryonnaires ?\nQuels examens sont utilisés pour étudier les feuillets ?\nPeut-on détecter des anomalies des feuillets ?\nQuels signes indiquent des problèmes embryonnaires ?\nLes feuillets peuvent-ils être visualisés directement ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Prostatic+Neoplasms&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Feuillets embryonnaires", "description": "Quels symptômes sont liés aux anomalies des feuillets ?\nLes anomalies des feuillets affectent-elles le développement ?\nComment les anomalies se manifestent-elles ?\nLes symptômes varient-ils selon le feuillet affecté ?\nLes symptômes sont-ils toujours présents à la naissance ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Prostatic+Neoplasms&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Feuillets embryonnaires", "description": "Comment prévenir les anomalies des feuillets embryonnaires ?\nLe dépistage prénatal aide-t-il à prévenir les anomalies ?\nLes vaccinations sont-elles importantes pendant la grossesse ?\nLe stress maternel influence-t-il le développement embryonnaire ?\nLes antécédents familiaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Prostatic+Neoplasms&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Feuillets embryonnaires", "description": "Quels traitements existent pour les anomalies des feuillets ?\nPeut-on prévenir les anomalies des feuillets ?\nLes traitements sont-ils efficaces ?\nY a-t-il des traitements expérimentaux ?\nLes traitements nécessitent-ils un suivi ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Prostatic+Neoplasms&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Feuillets embryonnaires", "description": "Quelles complications peuvent survenir avec des anomalies des feuillets ?\nLes complications sont-elles toujours visibles à la naissance ?\nLes anomalies des feuillets augmentent-elles le risque de maladies ?\nLes complications peuvent-elles être traitées ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Prostatic+Neoplasms&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Feuillets embryonnaires", "description": "Quels sont les facteurs de risque pour les anomalies des feuillets ?\nL'exposition à des toxines influence-t-elle le développement ?\nLes maladies maternelles affectent-elles le fœtus ?\nLe mode de vie maternel joue-t-il un rôle ?\nLes traitements médicaux peuvent-ils influencer le développement ?", "url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Prostatic+Neoplasms&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les feuillets embryonnaires ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'identification se fait par l'observation des couches cellulaires lors de l'embryogenèse." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour étudier les feuillets ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'échographie et l'imagerie par résonance magnétique (IRM) sont couramment utilisés." } }, { "@type": "Question", "name": "Peut-on détecter des anomalies des feuillets ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies peuvent être détectées par des tests génétiques et des échographies." } }, { "@type": "Question", "name": "Quels signes indiquent des problèmes embryonnaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des malformations ou des retards de développement peuvent indiquer des problèmes." } }, { "@type": "Question", "name": "Les feuillets peuvent-ils être visualisés directement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont généralement étudiés par des méthodes indirectes comme l'imagerie." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux anomalies des feuillets ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des malformations physiques et des troubles fonctionnels." } }, { "@type": "Question", "name": "Les anomalies des feuillets affectent-elles le développement ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des retards de croissance et des dysfonctionnements organiques." } }, { "@type": "Question", "name": "Comment les anomalies se manifestent-elles ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent se manifester par des malformations visibles ou des troubles internes." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le feuillet affecté ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque feuillet (ectoderme, mésoderme, endoderme) a des implications spécifiques." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents à la naissance ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, certaines anomalies peuvent se développer plus tard dans l'enfance." } }, { "@type": "Question", "name": "Comment prévenir les anomalies des feuillets embryonnaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée, l'évitement de substances nocives et des soins prénatals sont cruciaux." } }, { "@type": "Question", "name": "Le dépistage prénatal aide-t-il à prévenir les anomalies ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage permet d'identifier les risques et d'agir en conséquence." } }, { "@type": "Question", "name": "Les vaccinations sont-elles importantes pendant la grossesse ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines vaccinations protègent le fœtus contre des infections pouvant causer des anomalies." } }, { "@type": "Question", "name": "Le stress maternel influence-t-il le développement embryonnaire ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un stress élevé peut affecter le développement et augmenter le risque d'anomalies." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux d'anomalies peuvent augmenter le risque pour le fœtus." } }, { "@type": "Question", "name": "Quels traitements existent pour les anomalies des feuillets ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements varient de la chirurgie corrective à la thérapie génique selon l'anomalie." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des feuillets ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Certaines anomalies peuvent être prévenues par une bonne nutrition et des soins prénatals." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité dépend de la nature et de la gravité de l'anomalie détectée." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des recherches sont en cours sur des thérapies innovantes pour certaines anomalies." } }, { "@type": "Question", "name": "Les traitements nécessitent-ils un suivi ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour évaluer l'évolution et ajuster les soins." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies des feuillets ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des malformations graves, des troubles fonctionnels et des décès néonatals." } }, { "@type": "Question", "name": "Les complications sont-elles toujours visibles à la naissance ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Non, certaines complications peuvent se manifester plus tard dans l'enfance." } }, { "@type": "Question", "name": "Les anomalies des feuillets augmentent-elles le risque de maladies ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent prédisposer à des maladies chroniques ou à des troubles du développement." } }, { "@type": "Question", "name": "Les complications peuvent-elles être traitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées par des traitements médicaux ou chirurgicaux." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent avoir un impact significatif sur la qualité de vie de l'individu." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les anomalies des feuillets ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge maternel avancé, des antécédents familiaux et des infections." } }, { "@type": "Question", "name": "L'exposition à des toxines influence-t-elle le développement ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines environnementales peut augmenter le risque d'anomalies." } }, { "@type": "Question", "name": "Les maladies maternelles affectent-elles le fœtus ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines maladies, comme le diabète, peuvent augmenter le risque d'anomalies congénitales." } }, { "@type": "Question", "name": "Le mode de vie maternel joue-t-il un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme, l'alcool et une mauvaise nutrition sont des facteurs de risque importants." } }, { "@type": "Question", "name": "Les traitements médicaux peuvent-ils influencer le développement ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent être tératogènes et affecter le développement embryonnaire." } } ] } ] }

Sources (10000 au total)

Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?

The paradigm of focal therapy's role in metastatic patients is being challenged by evolving attitudes and emerging data. At the current time, specifically regarding prostate cancer, does the evidence ... We searched the literature via PubMed, MEDLINE, and Embase for studies from 2014 to the present addressing focal therapy with non-palliative intent in metastatic prostate cancer patients, emphasizing ... Current evidence is strongest, and in our opinion practice-changing, for prostate-directed RT in de novo metastatic patients with low metastatic burden. Metastasis-directed therapy with SBRT is consis...

Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.

There is a clinical need to identify patients with an elevated PSA who would benefit from prostate biopsy due to the presence of clinically significant prostate cancer (CSCaP). We have previously repo... To further develop and adapt the MiCheck® Prostate test so it can be performed using a standard clinical chemistry analyzer and characterize its performance using the MiCheck-01 clinical trial sample ... About 358 patient samples from the MiCheck-01 US clinical trial were used for the development of the MiCheck® Prostate test. These consisted of 46 controls, 137 non-CaP, 62 non-CSCaP, and 113 CSCaP.... Serum analyte concentrations for cellular growth factors were determined using custom-made Luminex-based R&D Systems multi-analyte kits. Analytes that can also be measured using standard chemistry ana... Logistic regression modeling with Monte Carlo cross-validation was used to identify Human Epidydimal Protein 4 (HE4) as an analyte able to significantly improve the algorithm specificity at 95% sensit... The MiCheck® logistic regression model was developed and consisted of PSA, %free PSA, DRE, and HE4. The model differentiated clinically significant cancer from no cancer or not-clinically significant ... The MiCheck® Prostate test identifies clinically significant prostate cancer with high sensitivity and negative predictive value (NPV). It can be performed in a clinical laboratory using a Roche Cobas...

New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.

Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinica... Proclarix and PHI were measured using samples of 344 men from two different centers. All patients underwent prostate biopsy, and among those, 188 men with PCa on biopsy had an additional radical prost... The cohort median age and PSA were 65 (interquartile range [IQR]: 60-71) and 5.6 (IQR: 4.3-7.2) ng/ml, respectively. CsPCa was diagnosed in 161 (47%) men based on the RP specimen. ROC analysis showed ... Results of this study show that both Proclarix and PHI accurately detect the presence of csPCa. The model combining Proclarix and PHI revealed the synergistic effect and improved the diagnostic perfor...

Detection of clinically significant prostate cancer by transperineal multiparametric magnetic resonance imaging-ultrasound fusion targeted prostate biopsy in smaller prostates.

Transperineal (TP) multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) has been shown to detect more clinically significant (cs) prostate cancer (PCa) than standard template biops... We identified all men who with suspicious lesions on mpMRI and underwent TP TBx (3-core) and concomitant SBx (20-core) in our single hospital from September 2019 to February 2021. Clinical, MRI and bi... Three hundred and one (n = 301) men were included. The median prostate volume by MRI was 45 ml. The patients were divided by prostate volume into three groups: ≤30ml group (19.9%), >30 to ≤45 ml group... Our data suggest that performing TBx with limited additional cores may potentially achieve the same csPCa detection rate as the combined SBx and TBx in smaller prostates....

Are elevated mitochondrial DNA fragments in prostatic inflammation a potential biomarker for prostate cancer?

We sought to determine whether two soluble forms with different size of mtDNA are linked to prostatic inflammation, and whether they discriminate prostate cancer (PCa) from inflammatory prostatic cond... Histopathologically diagnosed prostatitis, PCa and benign prostatic hyperplasia patients (n = 93) were enrolled in this study and they were categorized as with and without prostate inflammation. Quant... The urine mtDNA-79 and mtDNA-230 were significantly increased in patients with prostate inflammation compared with those in without inflammation. Here, 79-bp fragment of apoptotic origin was significa... Our results demonstrate that shorter cf-mtDNA fragment size in particular, increase in the presence of prostate inflammation in post-prostatic massage urine but both fragments could never improve seru...

The rapid assessment for prostate imaging and diagnosis (RAPID) prostate cancer diagnostic pathway.

To report outcomes within the Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) diagnostic pathway, introduced to reduce patient and healthcare burdens and standardize delivery of pre-biopsy... A total of 2130 patients from three centres who completed the RAPID pathway (3 April 2017 to 31 March 2020) were consecutively entered as a prospective registry. These patients were also compared to a... The median patient age and PSA level were 66 years and 6.6 ng/mL, respectively. Biopsy could be omitted in 43% of patients (920/2130). A further 7.9% of patients (168/2130) declined a recommendation f... The RAPID prostate cancer diagnostic pathway allows 43% of men to avoid a biopsy while preserving good detection of clinically significant cancers and low detection of insignificant cancers, although ...